- Home
- STTK vs CREX Comparison
STTK vs CREX Comparison
Compare STTK & CREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CREX
- Stock Information
- Founded
- STTK 2016
- CREX N/A
- Country
- STTK United States
- CREX United States
- Employees
- STTK N/A
- CREX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CREX EDP Services
- Sector
- STTK Health Care
- CREX Technology
- Exchange
- STTK Nasdaq
- CREX Nasdaq
- Market Cap
- STTK 54.4M
- CREX 44.8M
- IPO Year
- STTK 2020
- CREX N/A
- Fundamental
- Price
- STTK $1.08
- CREX $2.76
- Analyst Decision
- STTK Hold
- CREX Strong Buy
- Analyst Count
- STTK 3
- CREX 2
- Target Price
- STTK $2.00
- CREX $8.00
- AVG Volume (30 Days)
- STTK 329.4K
- CREX 63.7K
- Earning Date
- STTK 11-14-2024
- CREX 11-13-2024
- Dividend Yield
- STTK N/A
- CREX N/A
- EPS Growth
- STTK N/A
- CREX N/A
- EPS
- STTK N/A
- CREX 0.07
- Revenue
- STTK $6,435,000.00
- CREX $54,300,000.00
- Revenue This Year
- STTK $313.04
- CREX $22.92
- Revenue Next Year
- STTK N/A
- CREX $18.39
- P/E Ratio
- STTK N/A
- CREX $39.58
- Revenue Growth
- STTK 382.75
- CREX 31.80
- 52 Week Low
- STTK $0.94
- CREX $2.09
- 52 Week High
- STTK $11.76
- CREX $5.20
- Technical
- Relative Strength Index (RSI)
- STTK 40.71
- CREX 36.49
- Support Level
- STTK $1.07
- CREX $2.76
- Resistance Level
- STTK $1.38
- CREX $3.10
- Average True Range (ATR)
- STTK 0.13
- CREX 0.21
- MACD
- STTK 0.01
- CREX 0.03
- Stochastic Oscillator
- STTK 9.09
- CREX 33.33
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About CREX Creative Realities Inc.
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to global retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.